{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:15:17Z","timestamp":1790741717327,"version":"4.1.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2007,2,1]],"date-time":"2007-02-01T00:00:00Z","timestamp":1170288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2007,2]]},"DOI":"10.1016\/j.eururo.2006.08.043","type":"journal-article","created":{"date-parts":[[2006,9,12]],"date-time":"2006-09-12T11:32:28Z","timestamp":1158060748000},"page":"306-314","source":"Crossref","is-referenced-by-count":83,"title":["Antiandrogens in the Treatment of Prostate Cancer"],"prefix":"10.1016","volume":"51","author":[{"given":"Manfred P.","family":"Wirth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver W.","family":"Hakenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Froehner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2006.08.043_bib1","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/S0022-5347(05)65972-1","article-title":"A structured debate: immediate versus deferred androgen suppression in prostate cancer \u2013 evidence for deferred treatment","volume":"166","author":"Walsh","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2006.08.043_bib2","first-page":"293","article-title":"Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate","volume":"1","author":"Huggins","year":"1941","journal-title":"Cancer Res"},{"key":"10.1016\/j.eururo.2006.08.043_bib3","doi-asserted-by":"publisher","first-page":"8225","DOI":"10.1200\/JCO.2005.03.5311","article-title":"Early versus delayed androgen deprivation for prostate cancer: new fuel for an old debate","volume":"23","author":"Ryan","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2006.08.043_bib4","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0022-5347(05)00034-0","article-title":"Secondary hormonal therapy for advanced prostate cancer","volume":"175","author":"Lam","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2006.08.043_bib5","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1056\/NEJMoa041943","article-title":"Risk of fracture after androgen deprivation for prostate cancer","volume":"352","author":"Shahinian","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2006.08.043_bib6","doi-asserted-by":"publisher","first-page":"899","DOI":"10.4065\/80.7.899","article-title":"Adenocarcinoma of the prostate: epidemiological trends, screening, diagnosis, and surgical management of localized disease","volume":"80","author":"Routh","year":"2005","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.eururo.2006.08.043_bib7","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1046\/j.1464-410X.2003.04026.x","article-title":"The role of antiandrogen monotherapy in the treatment of prostate cancer","volume":"91","author":"Anderson","year":"2003","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2006.08.043_bib8","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1159\/000084427","article-title":"Comparative effects of bicalutamide versus orchidectomy on bone mineral density, bone remodelling and bone biomechanics in healthy rats","volume":"74","author":"Lefort","year":"2005","journal-title":"Urol Int"},{"key":"10.1016\/j.eururo.2006.08.043_bib9","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1200\/JCO.2004.01.174","article-title":"Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition","volume":"22","author":"Smith","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2006.08.043_bib10","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.1097\/01.ju.0000127738.94221.da","article-title":"Bicalutamide 150mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer","volume":"171","author":"Sieber","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2006.08.043_bib11","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/sj.pcan.4500799","article-title":"Bicalutamide (\u2018Casodex\u2019) 150mg in addition to standard care in patients with nonmetastatic prostate cancer: updated results from a randomised double-blind phase III study (median follow-up 5.1 y) in the early prostate cancer programme","volume":"8","author":"Wirth","year":"2005","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.eururo.2006.08.043_bib12","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1016\/j.eururo.2005.09.005","article-title":"Risks and benefits of hormonal manipulation as monotherapy or adjuvant treatment in localised prostate cancer","volume":"48","author":"Abrahamsson","year":"2005","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2006.08.043_bib13","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.radonc.2005.06.005","article-title":"Bicalutamide (\u2018Casodex\u2019) 150mg as adjuvant to radiotherapy in patients with localised or locally advanced prostate cancer: results from the randomised Early Prostate Cancer Programme","volume":"76","author":"Tyrrell","year":"2005","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.eururo.2006.08.043_bib14","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S1470-2045(05)70103-0","article-title":"Efficacy of tamoxifen and radiotherapy for prevention and treatment of gynaecomastia and breast pain caused by bicalutamide in prostate cancer: a randomised controlled trial","volume":"6","author":"Perdona","year":"2005","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2006.08.043_bib15","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1200\/JCO.2005.12.013","article-title":"Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer","volume":"23","author":"Boccardo","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2006.08.043_bib16","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.eururo.2004.12.003","article-title":"Efficacy and tolerability of radiotherapy as treatment for bicalutamide-induced gynaecomastia and breast pain in prostate cancer","volume":"47","author":"Van Poppel","year":"2005","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2006.08.043_bib17","unstructured":"Encyclopedia of cancer. Encyclopedia of Cancer: Antiandrogens: eNotes.com LLC (http:\/\/www.enotes.com\/cancer-encyclopedia), 2006."},{"key":"10.1016\/j.eururo.2006.08.043_bib18","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/j.1464-410X.2005.06051.x","article-title":"Bicalutamide 150mg plus standard care vs standard care alone for early prostate cancer","volume":"97","author":"McLeod","year":"2006","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2006.08.043_bib19","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/S0022-5347(05)67032-2","article-title":"Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup","volume":"164","author":"Iversen","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2006.08.043_bib20","doi-asserted-by":"publisher","first-page":"S48","DOI":"10.1097\/01.ju.0000096491.61731.38","article-title":"Bicalutamide monotherapy for early state prostate cancer","volume":"170","author":"Iversen","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2006.08.043_bib21","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/S0302-2838(02)00435-9","article-title":"Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer: updated results of a multicentric trial","volume":"42","author":"Boccardo","year":"2002","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2006.08.043_bib22","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1159\/000019634","article-title":"A randomised comparison of \u2018Casodex\u2019 (bicalutamide) 150mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer","volume":"33","author":"Tyrrell","year":"1998","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2006.08.043_bib23","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.eururo.2005.06.001","article-title":"EAU guidelines on prostate cancer","volume":"48","author":"Aus","year":"2005","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2006.08.043_bib24","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1038\/sj.pcan.4500531","article-title":"Is there a role for antiandrogen monotherapy in patients with metastatic prostate cancer?","volume":"4","author":"Kaisary","year":"1999","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.eururo.2006.08.043_bib25","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.eururo.2003.11.016","article-title":"Metastatic prostate cancer treated by flutamide versus cyproterone acetate. Final analysis of the \u201cEuropean Organization for Research and Treatment of Cancer\u201d (EORTC) Protocol 30892","volume":"45","author":"Schr\u00f6der","year":"2004","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2006.08.043_bib26","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1159\/000473717","article-title":"A prospective randomized study to compare goserelin acetate (Zoladex) versus cyproterone acetate (Cyprostat) versus a combination of the two in the treatment of metastatic prostatic carcinoma","volume":"29","author":"Thorpe","year":"1996","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2006.08.043_bib27","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.1200\/JCO.2004.04.579","article-title":"American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer","volume":"22","author":"Loblaw","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2006.08.043_bib28","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1001\/jama.294.2.238","article-title":"Androgen deprivation therapy for prostate cancer","volume":"294","author":"Sharifi","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.eururo.2006.08.043_bib29","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0090-4295(03)00145-6","article-title":"Finasteride and flutamide therapy in patients with advanced prostate cancer: response to subsequent castration and long-term follow-up","volume":"62","author":"Oh","year":"2003","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2006.08.043_bib30","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/S0090-4295(01)01213-4","article-title":"Bicalutamide (Casodex) 150mg as immediate therapy in patients with localized or locally advanced prostate cancer significantly reduces the risk of disease progression","volume":"58","author":"Wirth","year":"2001","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2006.08.043_bib31","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1097\/01.ju.0000140159.94703.80","article-title":"Bicalutamide 150mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years","volume":"172","author":"Wirth","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2006.08.043_bib32","first-page":"361","article-title":"Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma","volume":"95","author":"Samson","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.eururo.2006.08.043_bib33","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1016\/S0140-6736(00)02163-2","article-title":"Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials","volume":"355","year":"2000","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2006.08.043_bib34","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/S0140-6736(02)09408-4","article-title":"Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial","volume":"360","author":"Bolla","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2006.08.043_bib35","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1056\/NEJM199912093412401","article-title":"Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer","volume":"341","author":"Messing","year":"1999","journal-title":"New Engl J Med"},{"key":"10.1016\/j.eururo.2006.08.043_bib36","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.eururo.2003.10.013","article-title":"Prospective randomized trial comparing flutamide as adjuvant treatment versus observation after radical prostatectomy for locally advanced, lymph node-negative prostate cancer","volume":"45","author":"Wirth","year":"2004","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2006.08.043_bib37","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/S0360-3016(01)01579-6","article-title":"Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate","volume":"50","author":"Pilepich","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2006.08.043_bib38","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/S0936-6555(03)00093-1","article-title":"Is bicalutamide equivalent to goserelin for prostate volume reduction before radiation therapy? A prospective, observational study","volume":"15","author":"Henderson","year":"2003","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.eururo.2006.08.043_bib39","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S0022-5347(17)36163-3","article-title":"Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome","volume":"149","author":"Kelly","year":"1993","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2006.08.043_bib40","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1097\/01.ju.0000106190.32540.6c","article-title":"Alternative antiandrogens to treat prostate cancer relapse after initial hormone therapy","volume":"171","author":"Kojima","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2006.08.043_bib41","doi-asserted-by":"publisher","first-page":"9611","DOI":"10.1158\/0008-5472.CAN-05-0817","article-title":"Antiandrogen bicalutamide promotes tumor growth in a novel androgen-dependent prostate cancer xenograft model derived from a bicalutamide-treated patient","volume":"65","author":"Yoshida","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.eururo.2006.08.043_bib42","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1111\/j.1464-410X.2005.05714.x","article-title":"Efficacy of nilutamide as secondary hormonal therapy in androgen-independent prostate cancer","volume":"96","author":"Nakabayashi","year":"2005","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2006.08.043_bib43","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1159\/000049762","article-title":"Orchidectomy following failure of antiandrogen monotherapy in patients with metastatic prostate cancer","volume":"40","author":"Tan","year":"2001","journal-title":"Eur Urol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283806010062?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283806010062?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,21]],"date-time":"2019-04-21T03:55:42Z","timestamp":1555818942000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283806010062"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,2]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,2]]}},"alternative-id":["S0302283806010062"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2006.08.043","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2007,2]]}}}